Cargando…
Advanced Squamous Cell Carcinoma of the Lung: Current Treatment Approaches and the Role of Afatinib
Options for the treatment of squamous cell lung carcinoma expanded in recent years with the introduction of the immune checkpoint inhibitors into routine clinical practice in both the first- and second-line settings but are still limited. As a result, pembrolizumab, given either alone or in combinat...
Autores principales: | Santos, Edgardo S, Hart, Lowell |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7519820/ https://www.ncbi.nlm.nih.gov/pubmed/33061419 http://dx.doi.org/10.2147/OTT.S250446 |
Ejemplares similares
-
Role of afatinib in the treatment of advanced lung squamous cell carcinoma
por: Vavalà, Tiziana
Publicado: (2017) -
New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib
por: Hirsh, Vera
Publicado: (2017) -
Development of treatment options for Chinese patients with advanced squamous cell lung cancer: focus on afatinib
por: Lu, Shun
Publicado: (2019) -
Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung
por: Lu, Shun, et al.
Publicado: (2018) -
Long-term efficacy of afatinib in a patient with squamous cell carcinoma of the lung and multiple ERBB family aberrations: afatinib in ERBB+ lung squamous cell carcinoma
por: Jian, Hong, et al.
Publicado: (2019)